Abbott Laboratories, which has a research center in Worcester, said it has asked the U.S. Food and Drug Administration and the European Medicines Agency to approve a new treatment for psoriasis.
Humira, the treatment is called, “is poised to dominate the $2 billion-plus psoriasis market,” Abbott said.
Abbott said nearly one in five patients who received Humira during testing were completely cleared of psoriasis symptoms, and half of all test patients reported a 90 percent clearing of the skin condition.
Abbott reported that due to adverse events, seven percent of patients discontinued the use of Humira during clinical trials.
Psoriasis is a chronic skin disease that makes itself known with red, raised, itchy, burning, scaly lesions.
